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ABSTRACT
While several new therapies are FDA-approved for bone-metastatic prostate 
cancer (PCa), patient survival has only improved marginally. Here, we report 
that chitosan nanoparticle-mediated delivery of miR-34a, a tumor suppressive 
microRNA that downregulates multiple gene products involved in PCa progression 
and metastasis, inhibited prostate tumor growth and preserved bone integrity in 
a xenograft model representative of established PCa bone metastasis. Expression 
of miR-34a induced apoptosis in PCa cells, and, in accord with downregulation of 
targets associated with PCa growth, including MET and Axl and c-Myc, also induced 
a form of non-canonical autophagy that is independent of Beclin-1, ATG4, ATG5 and 
ATG7. MiR-34a-induced autophagy is anti-proliferative in prostate cancer cells, as 
blocking apoptosis still resulted in growth inhibition of tumor cells. Thus, combined 
effects of autophagy and apoptosis are responsible for miR-34a-mediated prostate 
tumor growth inhibition, and have translational impact, as this non-canonical form of 
autophagy is tumor inhibitory. Together, these results provide a new understanding 
of the biological effects of miR-34a and highlight the clinical potential for miR-34a 
delivery as a treatment for bone metastatic prostate cancer.
INTRODUCTION
Prostate cancer (PCa) is the second leading cause 
of cancer-related deaths in men in the United States [1], 
with mortality due mainly to metastasis to the bone [2]. 
While several new therapeutic agents have been approved 
for the treatment of bone metastasis [3, 4], their ability to 
prolong life has been limited due to the rapid development 
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of resistance [2, 5]. One approach to combat resistance is 
through combination therapies targeting several pathways 
in both the cancer cells and their tumor-promoting 
microenvironment. A promising strategy utilizing the 
same principle is miRNA-based therapeutics, since a 
single miRNA can have multiple targets in both the tumor 
cells themselves and the tumor microenvironment [6-9]. 
Restoring the expression of a tumor suppressive miRNA 
that is downregulated in cancer cells through nanoparticle-
mediated delivery of mature miRNA mimics has been 
shown to decrease tumor growth in several pre-clinical 
models without toxic side effects [10-13]. 
We used an unbiased systems-based approach to 
identify miRNAs that are downregulated in prostate 
cancer with the goal of targeting multiple gene products 
that are overexpressed in this disease and that promote 
tumor progression and bone metastasis. This approach 
led to identifying miR-34a, a tumor suppressive miRNA 
that is downregulated in the advanced stages of prostate 
cancer. Importantly, miR-34a targets several gene products 
associated with advanced PCa, including c-Myc, MET 
and Axl in tumor cells [12, 14, 15] and Tgif2 in the bone 
microenvironment [16]. Additionally, previous studies 
have demonstrated that miR-34a delivery can inhibit the 
growth of PCa xenografts in immunodeficient mice [12, 
15]. However, the complex biologic processes mediated 
by miR-34a that lead to tumor inhibition are not well 
described. Besides apoptosis, pathways that promote 
cell death include: autophagy-associated cell death [17], 
autosis [18], paraptosis [19], entosis [20], ferroptosis [21] 
and programmed necrosis [22], all of which can contribute 
to tumor inhibition. Among them, only autophagy has 
been described as both pro-tumorigenic by promoting 
survival under nutritional or chemotherapeutic stress 
and conversely, tumor suppressive, by promoting cancer 
cell death depending on the cellular context and different 
inducers of autophagy [17, 23-26]. These diametrically 
opposed biologic effects may be due, in part, to recent 
understanding that “canonical” and “non-canonical” 
autophagy pathways requiring different intermediates 
can elicit diverse effects in tumor cells [27, 28]. As 
decreased expression of the miR-34a targets, MET and 
Axl is associated with the induction of autophagy [29, 
30], understanding the form of autophagy induced by 
miR-34a in prostate cancer is important for therapeutic 
opportunities for miR-34a replacement in bone metastatic 
prostate cancer.
The goal of this study was to determine whether 
miR-34a delivery inhibits prostate tumor growth in 
the bone and the mechanism of miR-34a-mediated 
tumor inhibition. Our results demonstrate that chitosan 
nanoparticle-mediated delivery of miR-34a decreases 
established prostate tumor growth in the bone and 
preserves bone integrity. Mechanistically, miR-34a 
induces apoptosis along with a form of autophagy that 
inhibits prostate cancer cell proliferation by a mechanism 
independent of expression of Beclin-1, ATG4, ATG5 and 
ATG7. 
RESULTS
MiR-34a is downregulated in increasing stages of 
prostate cancer and in metastatic prostate cancer 
cell lines while its targets are overexpressed in 
metastatic PCa cells
To identify miRNAs that target at least seven or 
more genes frequently upregulated in prostate cancer 
relative to the normal prostate gland, we used GEO 
datasets (http://www.ncbi.nlm.nih.gov/gds, GSE6919) 
and then determined overlap with miRNAs that target 
genes upregulated in metastatic prostate cancer relative 
to primary cancer (GSE3325). Using this strategy, 13 
miRNAs were identified. We next determined which 
of these 13 miRNAs are downregulated in PCa [31-35] 
and identified two miRNAs, miR-18b and miR-34a, that 
met these criteria (Figure 1A). We next compared miR-
34a expression in the prostate cancer TCGA dataset 
(https://tcga-data.nci.nih.gov/tcga) with Gleason score 
(Figure 1B) and T stage (pathologic T) (Figure 1C), 
which demonstrates that miR-34a is downregulated in 
high-grade and advanced prostate cancer. To examine 
if a similar relationship occurred in human prostate 
cancer cell lines that could serve as a relevant, tractable 
experimental model, we quantified miR-34a expression 
levels by qPCR in LNCaP (which do not metastasize in 
immunocompromised mice), C42B4 (a LNCaP variant of 
low metastatic potential), PC3 (high metastatic potential) 
and PC3MM2 (selected for increased metastatic potential 
relative to parental PC3 cells). Expression of miR-34a was 
decreased by 8-fold in PC3 and by 12-fold in PC3MM2 
compared to C42B4 and LNCaP cells (Figure 1D). This 
result is in agreement with the clinical data that miR-34a 
expression is inversely proportional to increasing grade 
and stages of PCa. Next, we examined the expression 
of selected miR-34a targets (MET, Axl and c-Myc) 
associated with increased metastatic potential of PCa cell 
lines. Each of these genes is increased at mRNA (Figure 
S1A) and protein (Figure S1B) levels in the highly 
metastatic PC3MM2 and PC3 cells. To determine whether 
increasing miR-34a expression leads to downregulation 
of these targets, we transiently transfected low miR-34a 
expressing PC3 and PC3MM2 cells with negative control 
(N.C.) miRNA or a miRNA-34a (miR-34a) mimic. 
Transfection of miR-34a decreased mRNA (Figure S1C) 
and protein (Figure S1D) levels of MET, Axl, and c-Myc 
in PC3 and PC3MM2 cells. Our data thus demonstrate that 
miR-34a levels are decreased in high metastatic PCa cells 
compared to low metastatic cells, and increasing miR-34a 
expression in high metastatic PCa cells simultaneously 
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inhibited the expression of multiple targets that contribute 
to PCa progression and metastasis.
Systemic miR-34a delivery by chitosan 
nanoparticles inhibits prostate tumor growth in 
vivo
We next tested whether miR-34a delivery affected 
Figure 1: miR-34a is downregulated in prostate cancer and its delivery decreases sub-cutaneous tumor growth. A. 
GEO datasets were analyzed for prostate cancer and a Venn diagram representing downregulated miRNAs in prostate cancer that target 
genes upregulated in prostate cancer and prostate cancer metastasis is shown. B. TCGA dataset was analyzed for miR-34a expression in 
high-grade prostate cancer with Gleason score (6-9/10) and C. for different pathologic T staging (T2-T4). D. miR-34a expression was 
measured by qPCR using TaqMan assay and compared with U6 endogenous control for LNCaP, C42B4, PC3 and PC3MM2. E. Formalin 
fixed paraffin embedded (FFPE) slides were stained with H&E or in situ hybridization was performed for miR-34a and endogenous control 
for small nuclear RNA U6 (snoU6) (left panel). The mean intensities for 10 areas from each slide at 10x magnification were measured with 
NIS Elements software (right panel) F. Western blots for MET, Axl and c-Myc from sub-cutaneous tumor treated with control or miRa-34a. 
G. Tumor volume of sub-cutaneous PC3MM2 xenografts was measured by calipers for control and miR-34a treated group (n = 6). H. A 
representative image is shown for control and miR-34a-treated tumors with TUNEL (green), nuclear DAPI (blue) and CD31 (red) staining 
(left panel). TUNEL-positive cells from 10 fields per tumor were quantified using ImageJ software and the mean and standard deviation is 
plotted (right panel). 
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tumor growth and whether all three targets could be 
downregulated by its delivery in vivo. For these studies, 
tumors were first grown subcutaneously as described in 
the materials and methods. Next, miR-34a was delivered 
to these tumors systemically via tail vein injections. To 
deliver miR-34a, we chose chitosan (CH) nanoparticles 
that are composed of biodegradable, naturally occurring 
polysaccharides with low immunogenicity and toxicity 
[36, 37]. We observed robust expression of miR-34a in 
tumors following delivery of miR-34a-CH as visualized by 
in situ hybridization (Figure 1E). Expression of miR-34a 
correlated with downregulation of MET, Axl and c-Myc 
as determined by immunoblotting (Figure 1F). Delivery 
of miR-34a decreased subcutaneous tumor growth (Figure 
1G) and induced apoptosis as measured by an increase in 
TUNEL-positive cells (Figure 1H) in miR-34a treated 
tumors compared to control tumors. Collectively, these 
results demonstrate that nanoparticle-mediated delivery of 
miR-34a decreased the expression of its targets and tumor 
growth, as well as induced apoptosis in a subcutaneous 
model of prostate cancer.
Effects of miR-34a delivery on PCa tumor growth 
in the bone
Since bone metastasis is the leading cause of 
death in PCa, our focus was on determining the effects 
of systemic miR-34a-CH delivery on established tumors 
in an intra-femoral model to represent treatment of PCa 
bone metastasis. To first determine whether chitosan could 
deliver small RNAs to the bone, we delivered Cy5.5-
labeled siRNA through chitosan nanoparticles since the 
fluorescent signal from Cy5.5 can be detected by ex vivo 
imaging. PC3MM2-LG cells were injected in the femur 
of nude mice, and 10 days after tumor injection, unlabeled 
control or Cy5.5-labeled siRNA in chitosan nanoparticles 
were delivered intravenously. Fluorescence intensity was 
measured from harvested legs of animals sacrificed 3 days 
after siRNA delivery. An increase in Cy5.5-siRNA signal 
intensity was observed in the femur with tumor than in the 
femur without tumor (Figure S2) suggesting that siRNA 
delivered by chitosan nanoparticles is preferentially 
retained in the tumor growing inside the bone. Thus, 
chitosan nanoparticles were suitable for delivery of miR-
34a to the bone.
Figure 2: Systemic miR-34a delivery by chitosan nanoparticles decreases prostate tumor growth in bone in an intra-
femoral model. A. Bioluminescence activity to assess for intra-femur tumor growth was measured using an IVIS 200 for control and 
miR-34a groups (n = 5). B. Representative MRI images taken at the end of the experiment of the femurs (red dotted line) for control-CH 
and miR-34a-CH treated mice are shown. Tumor volume in the femur was measured before (left panel) and after (right panel) miR-34a 
delivery. C. Micro CT images for two control-CH and two miR-34a-CH treated mice. Red arrows indicate bone lesions. * denotes p < 0.05 
as measured by Student’s t test. 
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We next determined the effect of systemic miR-34a 
delivery on established tumors in the femur to best mimic 
treatment of bone metastasis. We injected PC3MM2-LG 
(transfected to express luciferase and GFP) cells into the 
femurs of nude mice and monitored tumor growth by 
bioluminescence activity and MRI. After ten days, when 
tumors were evident in the femurs (as demonstrated by 
MRI), mice were randomized and treated with either 
control-miRNA (scrambled sequence of negative control 
miRNA that does not interfere with known miRNA 
functions) or miR-34a chitosan nanoparticles every three 
days for three weeks through systemic administration. 
Delivery of miR-34a robustly decreased tumor growth 
relative to control group (measured by bioluminescence 
activity of PC3MM2-LG cells) (Figure 2A) and tumor 
volume (measured by MRI) (Figure 2B, right panel) of 
established prostate tumors in the bone. PC3MM2 cells 
cause lytic reactions in the bone. Importantly, miR-
34a delivery led to a preservation of bone integrity as 
visualized by micro CT analysis (Figure 2C). Collectively, 
our results demonstrate that miR-34a’s anti-tumor effects 
were superior in an intra-femoral PCa model compared 
to a sub-cutaneous model, suggesting that miR-34a may 
mediate tumor suppressive effects by targeting both the 
tumor as well as the bone microenvironment. 
MiR-34a inhibits metastatic properties in PC3 
cells
To understand the mechanism of miR-34a-induced 
tumor inhibition, we expressed miR-34a in PC3 cells 
through transient transfection of miR-34a mimics and 
studied the biological effects. Expression of miR-34a 
decreased the ability of PC3 cells to migrate by 50% 
(Figure S3A), and the ability to invade by 75% (Figure 
S3B). Since miR-34a expression was maintained 96 
hours post-transfection (data not shown), we determined 
the effects of increasing miR-34a expression on cell 
proliferation. Transfection of miR-34a decreased cell 
proliferation compared to N.C. (Figure S3C). We next 
performed cell cycle analysis using propidium iodide 
(PI) at various times after N.C. or miR-34a transfection. 
A 4-fold decrease in S-phase was observed beginning at 
48 hours, which was maintained through 96 hours post-
transfection (Figure S3D). After 72 hours, the sub G1 
phase increased by 1.5 fold in miR-34a overexpressing 
cells, reaching a maximum of 2-fold at 96 hours relative 
to N.C. transfected cells (Figure S3D). These results 
demonstrate that miR-34a-mediated decreased cell 
proliferation is due, at least in part, to increased cell death. 
To determine what type(s) of cell death were occurring, 
we used a GFP-Certified® Apoptosis/Necrosis detection 
kit as described in the materials and methods. An increase 
in early (AnnVEnzoGold+/7AAD-) and late apoptotic 
(AnnVEnzoGold+/7AAD+) cell populations was observed 
at 72 and 96 hours post miR-34a transfection compared 
to N.C. transfected cells (Figure S3E). Collectively, our 
data demonstrate that increasing miR-34a expression has 
direct effects on tumorigenic and metastatic potential of 
PCa cells through inducing apoptosis, decreasing cell 
proliferation, and decreasing cell migration and invasion.
MiR-34a induces autophagy
Since downregulation of MET or Axl has been 
shown to induce both apoptosis and autophagy in different 
cancer types [29, 30], we asked whether miR-34a induces 
autophagy in addition to apoptosis in PCa cells. We first 
analyzed Beclin-1 expression in cells transfected with 
N.C. or miR-34a, as it is involved in vesicle nucleation 
and autophagosome formation [38, 39]. An increase in 
Beclin-1 protein, but not mRNA expression (data not 
shown), was observed at 48 hours in miR-34a transfected 
cells, and continued throughout the time course examined 
(Figure 3A). Next, we examined the conversion of LC3BI 
to LC3BII, a hallmark of autophagosome maturation [40]. 
Increased LC3BII levels were observed 48 hours after 
miR-34a transfection, and these increased levels were 
maintained at 72 and 96 hours post-transfection (Figure 
3A). 
To determine whether autophagic structures were 
formed in miR-34a transfected cells, transmission electron 
microscopy (TEM) was performed. As shown in Figure 
3B, miR-34a transfection led to an accumulation of 
autophagosome (AP)-like structures (black arrows) as 
well as autolysosome (AL)-like structures (red arrows) 
that were not observed in N.C. cells. This result confirms 
that transfection of miR-34a in PC3 cells led to the 
accumulation of autophagosomes and autolysosomes. To 
monitor the autophagic flux induced by miR-34a in a real-
time manner (indicative of the dynamic autophagic flux 
occurring from initiation to maturation of autophagosomes 
and fusion with lysosomes), cells pre-labeled with tandem 
monomeric RFP-GFP-tagged LC3 [41] and transfected 
with N.C. or miR-34a were visualized by time-lapse 
microscopy [40]. We observed that the signal from GFP+ 
and RFP+ vesicular structures in the N.C. and miR-34a 
transfected cells merged at 120 minutes (Figure 3C and 
Supporting Movies 1 and 2). However, at increasing 
times, miR-34a caused a sustained accumulation of RFP+ 
vesicular structures in the cytoplasm compared to the N.C. 
cells (Figure 3C, red cells; Supporting Movie 2 compared 
to Supporting Movie 1), indicative of accumulation of late-
stage autophagic vesicles including fused autolyosomes, 
since the RFP signal is more stable than GFP in the acidic 
compartment of the lysosomes [40]. 
To quantitatively measure the population of acidic 
vesicular organelles (AVOs) that were accumulated in the 
cytoplasm during late-stage autophagy, cells transfected 
with N.C. or miR-34a for increasing times were stained 
with acridine orange and analyzed by flow cytometry 
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Figure 3: miR-34a induces autophagy in PC3 cells. A. Western blots for LC3B, Beclin-1 and GAPDH from negative control 
(N.C.) and miR-34a transfected cells at indicated time points. B. Transmission electron microscopy (TEM) images at 2500X and 25000X 
magnification were captured for N.C. and miR-34a transfected PC3 cells at 72h. Black arrows indicate autophagosome (AP)-like and red 
arrows indicate autolysosome (AL)-like structures. C. Screen shots from time-lapse microscopy monitoring autophagic flux for PC3 cells 
labeled with GFP-RFP-tagged LC3 and transfected with either N.C. or miR-34a. D. Western blots for MET, cleaved caspase 3, LC3B and 
GAPDH from PC3 cells pre-treated with NS3694 (100nM) for 24 h, followed by N.C. or miR-34a transfection for 72 hours. E. Proliferation 
of cells pre-treated with NS3694 (100nM) for 24h, followed by N.C. or miR-34a transfection for indicated time points. * denotes p < 0.05 
as measured by Student’s t test.
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as described in materials and methods. An increase in 
acridine orange-positive cells was observed in miR-34a-
expressing cells at 48 hours with further increases noted 
at 72 and 96 hours (Figure S4A), mirroring the time 
frame observed for miR-34a-mediated increased LC3BII 
levels. Using confocal microscopy, we demonstrated 
that transfection of miR-34a for 72 hours increased the 
accumulation of acridine orange in the cytoplasm of cells 
(Figure S4B), further corroborating the FACS results. We 
next tested whether miR-34a led to degradation of p62/
SQSTM1, a ubiquitin-binding scaffold protein that serves 
as link between autophagy process and protein degradation 
[42] in PC3 cells. Transfection with miR-34a decreased 
p62/SQSTM1 levels compared to control and N.C. 
transfected cells (Figure S4C). We further tested whether 
blocking autophagy by using hydroxychloroquine (HCQ) 
that prevents fusion of autophagosomes with lysosomes 
[43] affects miR-34a induced autophagy. HCQ prevented 
p62 degradation while miR-34a led to reduced levels of 
p62 in PC3 cells (Figure S4C). Pre-treatment with HCQ 
prevented miR-34a-mediated degradation of p62, which 
indicates that HCQ impedes miR-34a induced autophagy. 
Thus, the combined results demonstrate that miR-34a 
induces autophagy in PC3 cells. 
To determine whether miR-34a-induced autophagy 
was inhibiting or promoting PC3 cell proliferation, 
we used the apoptosis inhibitor, NS3694 to inhibit the 
formation of the apoptosomes, followed by transfection 
of N.C. or miR-34a for 72 hours. The ability of NS3694 
to block docetaxel-induced apoptosis (as determined by 
inhibition of caspase 3 activation) is shown in Figure S4D. 
Transfection with miR-34a decreased MET expression 
and increased LC3BII and cleaved caspase 3 levels even 
in the presence of the apoptosis inhibitor (Figure 3D). 
Further, NS3694 was unable to block miR-34a’s potent 
anti-proliferative effects (Figure 3E). These results suggest 
that autophagy induced by miR-34a was associated with 
decreased proliferation. 
We next determined whether miR-34a induced 
autophagy in other PCa cell lines. Transfection of miR-
34a increased Beclin-1expression in PC3MM2 cells and 
LC3BII levels in both PC3MM2 and C42B4 cells (Figure 
S4E). These increases were similar to those observed in 
the PC3 cells (Figure 3A and Figure S4E). This result was 
supported by the increase in acridine orange-positive cells 
observed in both PC3MM2 and C42B4 cells (Figure S4F) 
following miR-34a transfection. These combined results 
indicate that miR-34a induces autophagy in several PCa 
cell lines.
MiR-34a-induced autophagy is Beclin-1-
independent
Since miR-34a increased Beclin-1 protein expression, 
we tested whether miR-34a-induced autophagy is mediated 
through Beclin-1. A lentiviral shRNA was used to decrease 
expression of Beclin-1 in PC3 cells, which were then 
transfected with N.C. or miR-34a for 72 hours. Expression 
of Beclin-1 protein (Figure 4A) and mRNA (Figure 4B) 
was significantly decreased following lentiviral infection, 
while ATG7 mRNA expression was unaffected (Figure 
4C). We next examined the effects of Beclin-1 knockdown 
on miR-34a-induced autophagy by determining LC3BII 
levels. Surprisingly, miR-34a expression increased 
LC3BII levels, independent of Beclin-1 knockdown 
(Figure 4A). This result was supported by the increase 
in acridine orange positive cells following miR-34a 
expression independent of Beclin-1 (Figure 4D). Further, 
miR-34a was still effective in inhibiting MET (Figure 4A 
and 4E) and Axl expression (Figure 4F). Consistent with 
our previous data, transfection of miR-34a in PC3 cells 
decreased proliferation compared to N.C. transfection 
(Figure 4G), while in shBeclin-1 cells, miR-34a also 
decreased cell proliferation compared to N.C. (Figure 4G). 
Additionally, cell cycle analysis demonstrated a 5-fold 
increase in the sub G1 fraction of cells following miR-
34a expression in both control PC3 cells and in PC3 cells 
with Beclin-1 knockdown (Figure 4H). These data suggest 
that miR-34a-induced effects on autophagy, cell cycle and 
cell proliferation are mediated by a Beclin-1-independent 
mechanism.
MiR-34a induces ATG5- and ATG7-independent 
autophagy
Since several forms of non-canonical autophagy, 
including Atg5/Atg7-independent “alternative” 
macroautophagy have been reported [44, 45], we next 
determined whether miR-34a-induced autophagy was 
mediated through ATG5 and ATG7. In the canonical 
autophagy pathway, these ATGs are involved in 
autophagosome elongation and completion [46]. We 
used two siRNA sequences to robustly knockdown ATG5 
and ATG7 expression in PC3 cells and then transfected 
them with N.C. or miR-34a. Success of knockdown 
was determined by immunoblotting and qPCR. ATG5 
and ATG7 were reduced more than 90% at the protein 
(Figure 5A and Figure 5G) and mRNA (Figure 5B and 
Figure 5H) levels by corresponding siRNAs. Specificity 
of knockdown is indicated, as mRNA expression of ATG7 
in siATG5 (Figure 5C) and ATG5 in siATG7 (Figure 5I) 
cells was unaffected. As expected, siATG5 and siATG7 
decreased LC3II levels compared to N.C. (Figure 5A and 
5G- lane 1 vs. lane 3 and lane 1 vs. 5) confirming that 
knocking down expression of these gene products inhibits 
basal autophagy. We then examined the effects of miR-34a 
on autophagy when either ATG5 or ATG7 were reduced by 
siRNA knockdown. As observed previously (Figure 3A), 
miR-34a expression increased LC3BII compared to N.C. 
(Figure 5A and 5G lane 1 vs. 2). Surprisingly, in the cells 
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in which either ATG5 or ATG7 were reduced, miR-34a 
still increased LC3BII levels compared to N.C. (Figure 
5A and 5G, compare lane 3 and 4 and lane 5 and 6). As 
expected, both c-Met (Figure 5D and 5J) and Axl (Figure 
5E and 5K) mRNA levels were decreased following miR-
34a transfection, regardless of ATG5 and ATG7 status. 
These results indicate that reduced expression of ATG5 or 
ATG7 did not block the autophagic flux induced by miR-
34a, nor affected its downstream targets.
To determine miR-34a’s effects on cell proliferation 
in PC3 cells and PC3 cells in which ATG5 or ATG7 was 
reduced by siRNAs, we used a fluorescent DNA dye to 
quantitate cell numbers as previously described [47]. 
Consistent with our previous data (Figure S3C), miR-
34a transfection decreased proliferation compared to 
N.C. transfected cells (Figure 5F and 5L-column 1 vs. 
2). Additionally, reduced ATG5 or ATG7 expression 
decreased both basal autophagy and cell proliferation 
compared to N.C. (Figure 5F and 5L-column 3 and 4 vs. 
column 1), consistent with previous reports [47]. However, 
Figure 4: miR-34a induces autophagy, cell cycle arrest and decreases cell proliferation independently of Beclin-1. A. 
Western blot for Beclin-1, LC3B, MET and GAPDH for PC3 and shBeclin-1 cells with N.C. or miR-34a transfection. mRNA expression for 
B. Beclin-1 and C. ATG7 in PC3 and shBeclin-1 cells with N.C. or miR-34a transfection. D. Acridine orange-positive cells were quantified 
by Gallios FACS at 72 hours post- N.C. or miR-34a transfection. mRNA expression for E. c-Met and F. Axl in PC3 and shBeclin-1 cells 
with N.C. or miR-34a transfection. G. Proliferation of cells at indicated time points for PC3 and shBeclin-1 cells with N.C. or miR-34a 
transfection. H. Cell cycle analysis following propidium iodide staining and FACS for different cell cycle phases in PC3 and shBeclin-1 
cells with 72h of N.C. or miR-34a transfection. * denotes p < 0.05 as measured by Student’s t test.
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miR-34a transfection further decreased proliferation in 
cells with reduced ATG5 (Figure 5F-column 3 vs. 4 and 
5 vs. 6) and ATG7 (Figure 5L-column 3 vs. 4 and 5 vs. 
6). This result suggests that ATG5 and ATG7 affect basal 
autophagy and cell proliferation, but not miR-34a-induced 
autophagy and its effect on cell proliferation.
To minimize any potential effects due to transient 
transfection, we created PC3 cells that stably expressed 
doxycycline-inducible shATG7. Upon addition of 
doxycycline, ATG7 protein (Figure S5A) and mRNA 
Figure 5: miR-34a induces autophagy and decreases cell proliferation independently of ATG5 and ATG7. A. Western 
blots for ATG5, LC3B and GAPDH in PC3 control cells and PC3 cells with two siATG5 sequences followed by N.C. and miR-34a 
transfection. mRNA expression for B. ATG5, C. ATG7, D. c-Met and E. Axl for PC3 control cells and PC3 cells with two siATG5 
sequences with N.C. or miR-34a transfection after 72h as measured by qPCR. F. Proliferation of cells at indicated time points for PC3 
control cells and PC3 cells with two siATG5 sequences followed by N.C. or miR-34a transfection. G. Western blots for ATG7, LC3B and 
GAPDH in PC3 control cells and PC3 cells with two siATG7 sequences followed by N.C. and miR-34a transfection. mRNA expression for 
H. ATG7, I. ATG5, J. c-Met and K. Axl for PC3 control cells and PC3 cells with two siATG7 sequences with N.C. or miR-34a transfection 
after 72h as measured by qPCR. L. Proliferation of cells at indicated time points for PC3 control cells and PC3 cells with two siATG7 
sequences followed by N.C. or miR-34a transfection. * denotes p < 0.05 as measured by Student’s t test. 
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(Figure S5B) levels were decreased without affecting 
the levels of ATG5 (Figure S5C), confirming the 
inducible knockdown of ATG7. To examine the effects of 
shATG7 on miR-34a-induced autophagy, we determined 
LC3BII levels. Consistent with our results in PC3 cells 
transiently transfected with siATG7, an increase in LC3BII 
expression was still observed with miR-34a in both non-
induced (Figure S5A lane 1 vs. 2) and doxycycline (Dox)-
induced shATG7 (Figure S5A lane 3 vs. 4) cells. These 
results support that miR-34a effects on LC3B conversion 
are independent of ATG7. Similar to siATG7, miR-34a 
expression still decreased the mRNA levels of c-Met 
(Figure S5D) and Axl (Figure S5E) in both non-induced 
and shATG7 conditions. In addition, shATG7 decreased 
proliferation compared to non-induced cells (Figure 
S5F-column 1 vs. 3) while miR-34a further decreased 
proliferation in cells with reduced ATG7 expression 
(Figure S5F-column 3 vs. 4). Taken together, our data 
suggest that miR-34a induces autophagy independently of 
ATG5 and ATG7.
MiR-34a overexpression effects autophagy 
independent of ATG4 knockdown
Since the intermediates involved in the downstream 
processing of LC3II (ATG7 and ATG5) did not affect 
autophagy induced by miR-34a, we examined whether 
ATG4, a cysteine protease involved both upstream in the 
conversion of pro-LC3 to LC3I and downstream in the 
recycling of LC3II to LC3I [48, 49], was required for miR-
Figure 6: miR-34a induces autophagy independently of ATG4. All four isoforms of ATG4 were simultaneously knocked down 
in PC3 cells using pooled siRNAs. A. Western blots for ATG4A-D, LC3B, p62, MET and GAPDH. mRNA expression for B. ATG4A, 
C. ATG4B, D. ATG4C, E. ATG4D, F. c-Met and G. Axl for siControl and siATG4 cells with N.C. or miR-34a transfection after 72h as 
measured by qPCR. H. Cell cycle analysis following propidium iodide staining and FACS for different cell cycle phases in siControl and 
siATG4 cells with 72h of N.C. or miR-34a transfection I. Proliferation of cells at indicated time points for siControl and siATG4 cells with 
N.C. or miR-34a transfection. * denotes p < 0.05 as measured by Student’s t test.
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34a-induced autophagy. ATG4 has four isoforms, ATG4A, 
ATG4B, ATG4C and ATG4D with overlapping and distinct 
functions [48]. ATG4B was identified as a direct target 
of miR-34a in chronic myelogenous leukemia (CML), 
and the knockdown of ATG4B in CML led to impaired 
autophagic flux with an increase in LC3II levels and 
accumulation of p62 [50]. We thus determined whether 
miR-34a mediates its effects on autophagy through ATG4. 
To eliminate the redundant effects of ATG4 isoforms, we 
used pooled siRNA sequences to knock down all four 
isoforms simultaneously in PC3 cells and then transfected 
the cells with either control (N.C.) or miR-34a mimics. All 
isoforms of ATG4 were reduced with siRNA sequences, in 
protein (Figure 6A), as well as in mRNA (Figure 6B-6E) 
expression. Consistent with ATG4’s role in LC3 recycling 
in the canonical autophagy pathway [49, 50], knockdown 
of the ATG4 isoforms increased LC3BII and led to p62 
accumulation (Figure 6A). However, unlike the results 
in CML, miR-34a had only a minor effect on decreasing 
ATG4B protein expression (Figure 6A), suggesting that 
ATG4B is not a direct target of miR-34a in PC3 cells. 
Consistent with our above results, miR-34a expression 
in PC3 cells led to increased LC3BII levels (Figure 6A). 
Similarly, in line with the miR-34a induction of autophagy, 
p62 levels were decreased (Figure 6A). We next analyzed 
the effects of miR-34a transfection in siATG4 cells. We 
observed increased LC3BII levels and accumulation 
of p62, similar to what was observed with knockdown 
of ATG4 isoforms (Figure 6A). Targets of miR-34a 
are decreased at protein (Figure 6A) as well as mRNA 
levels (Figure 6F and 6G) with miR-34a expression 
in siATG4 cells similar to siControl cells. Cell cycle 
analysis demonstrated an increase in the sub G1 fraction 
of cells and a decrease in S-phase following miR-34a 
transfection in both control and siATG4 cells (Figure 6H). 
Correspondingly, there was a decrease in cell proliferation 
with miR-34a in siControl cells and miR-34a transfection 
further decreased proliferation in siATG4 cells (Figure 
6I). These results suggest that while knockdown of ATG4 
leads to impaired autophagy consistent with a previous 
report [50], miR-34a induces autophagy independent of 
ATG4 expression in prostate cancer cells. 
DISCUSSION
We demonstrate that nanoparticle-mediated delivery 
of miR-34a inhibits the growth of bone-localized PCa. 
Overexpression of miRNA-34a induces a non-canonical 
form of autophagy in addition to apoptosis, inhibiting cell 
proliferation and promoting cell death in PCa cell lines of 
high metastatic potential. These data suggest that indirect 
induction of a non-canonical form of autophagy, through 
inhibition of targets such as MET and Axl contributes to 
inhibition of prostate tumor growth, as shown in the model 
in Figure 7. Our study highlights the tumor suppressive 
role of miR-34a-induced autophagy with clinical 
implications in the treatment of advanced bone metastatic 
PCa, the leading cause of death in prostate cancer. At 
present, the treatments available for this stage of the 
disease have limited success due to the rapid development 
of de novo or acquired resistance. Thus, therapeutic 
strategies that downregulate the expression of genes 
involved in multiple pathways that promote PCa growth in 
the bone may be more efficacious than targeted inhibitors 
with a more limited spectrum of targets, such as dasatinib 
and cabozantinib that have failed in phase 3 clinical trials 
[51]. MiRNA replacement therapy in advanced prostate 
cancers presents as an alternate treatment strategy for 
PCa bone metastasis due to their ability to target and 
downregulate oncogenic pathways in the cancer cells as 
well as in the bone microenvironment. 
MiR-34a was chosen to test its therapeutic potential 
in a model for metastatic PCa growth in the bone based on: 
1) its ability to target numerous gene products that promote 
PCa progression; 2) its downregulation in progressive 
stages of PCa; and 3) previous work demonstrating 
its delivery decreases tumor growth in orthotopic and 
subcutaneous PCa xenograft models [12, 15]. Our study 
demonstrates greater efficacy of miR-34a delivery in 
inhibiting tumor growth in the bone compared to a sub-
cutaneous model implicating the anti-tumorigenic effects 
on both tumor cells and the bone microenvironment. 
Recently, Krzeszinski et al. [16] demonstrated that the 
miR-34a-mediated inhibition of breast and melanoma 
bone metastases was attributed exclusively to inhibiting 
osteoclast activity through downregulation of Tgif2, 
essential for osteoclast function [16]. Since osteoclast 
activation is implicated in bone remodeling and growth 
of PCa cells in the bone [52, 53], inhibition of Tgif2 
and other miR-34a targets in the microenvironment may 
explain the more profound effects on tumor growth in the 
bone than were observed subcutaneously, and demonstrate 
the importance of targeting both the tumor cell and the 
tumor microenvironment. Thus, replacement of miR-
34a with its ability to target and inhibit oncogenic gene 
products at both compartments presents as an alternate 
treatment strategy in metastatic prostate cancer.
Given the large number of potential miR-34a 
targets, some of which appear to be cell type-specific 
[54], and differences in potential “driver” oncogenes 
that promote metastatic growth among different cancer 
types, understanding the complexity of the biology due 
to miR-34a replacement therapy is critical to understand 
in which tumors delivery of this miRNA might lead to 
anti-tumor effects, and also the mechanisms by which 
this occurs. Downregulation of the miR-34a targets, MET 
and Axl have been shown to increase apoptosis as well 
as to induce autophagy [29, 30]. Accordingly, in prostate 
cancer cells, miR-34a led to delayed autophagy by classic 
criteria, including presence of autophagic structures 
as determined by TEM, immunoblotting for molecular 
markers of autophagy, and time-lapse microscopy to 
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demonstrate autophagic flux. However, miR-34a-induced 
autophagy in these cells still occurred even when the well-
studied intermediates of the canonical pathway (Beclin-1, 
ATG5, ATG7 and ATG4) were greatly decreased in 
expression by siRNAs/shRNAs (sufficiently decreased 
to block basal autophagy), suggesting a non-canonical 
form of this process. This non-canonical autophagy is 
anti-proliferative, as cell proliferation was decreased with 
miR-34a transfection even after inhibition of apoptosis.
Several examples of “non-canonical” autophagy 
have recently been reported. Similar to our results with 
Beclin-1 knockdown, Scarlatti, et al. [55] demonstrated 
that resveratrol induces Beclin-1-independent autophagy 
in breast cancer cells. Nishida et al. [45] reported an 
ATG5/ATG7-independent macroautophagy that did not 
increase LC3II levels. In contrast to this study, our results 
with miR-34a transfection increased LC3BII even in 
ATG5 and ATG7 knockdown cells, suggesting that other 
intermediates may be important in miR-34a-induced 
autophagy. Knockdown of ATG4B, a direct miR-34a target 
in CML impairs autophagy [50]. However, miR-34a had 
only a minor affect in decreasing ATG4B expression, 
suggesting that unlike CML cells [50], ATG4B is not 
likely a target of miR-34a in prostate cancer cells. Another 
example of cell type specificity of miR-34a targets is 
from the work of Liu et al. [56], who demonstrated 
that miR-34a inhibited autophagy under conditions of 
starvation or chemotherapy, leading to enhanced cell 
death in retinoblastoma cells. In that study, miR-34a 
altered autophagy by inhibiting HMGB1 expression 
Figure 7: Schematic representation of signaling pathways by which miR-34a inhibits prostate cancer growth. MiR-34a 
inhibits the expression of targets involved in promoting PCa progression and metastasis (c-Myc, Axl and MET). Inhibition of these targets 
activates both apoptosis and a non-canonical autophagy independent of Beclin-1, ATG4, ATG5 and ATG7. Both autophagy and apoptosis 
contribute to inhibition of prostate tumor growth.
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[56]. In contrast, HMGB1 expression was not affected in 
prostate cancer cells by miR-34a (data not shown). Thus, 
miR-34a’s effects on autophagy may differ depending 
on the conditions by which autophagy is induced and 
downregulation of different targets in different tissues 
(such as MET and Axl in prostate cancer cells). As the 
“forms” of autophagy are ever increasing, we speculate 
that different inducers mediate the autophagy process 
through different signal transduction pathways, which may 
account for the varied biological effects in different tumor 
types observed by miR-34a replacement, with critical 
implications as to whether autophagy is tumor promoting 
or suppressive or directly leads to apoptosis.
In conclusion, our study highlights the role of 
miR-34a in inducing autophagy along with apoptosis. 
Our study has therapeutic implications in the clinic, and 
emphasizes the need to understand the direct inducers and 
intermediates that lead to different forms of autophagy, so 
that predictions can be made as to whether this biologic 




Transient transfections were performed using 
Lipofectamine 2000 transfection reagent (Invitrogen, 
Carlsbad, CA) for 24 hours, or 48, 72 or 96 hours for time 
course experiments. Briefly, 100,000 or 200,000 cells 
were placed in a 6-well plate in growth media without 
antibiotics 24 hours prior to transfection. Cells were then 
transfected with either negative control (N.C.) miRNA 
or miR-34a mimics (Ambion, Austin, TX) at a final 
concentration of 30 nM, according to the manufacturer’s 
instructions. 
RNA isolation and quantitative polymerase chain 
reaction (qPCR)
Total RNA was isolated from cell lines using 
the mirVana kit (Ambion, Austin, TX) according to the 
manufacturer’s instructions and 10 ng of total RNA was 
reverse transcribed using the TaqMan miRNA reverse 
transcription kit (Applied Biosystems, Foster City, CA). 
Quantitative PCR (qPCR) was performed on the Agilent 
3000P system using the human miR-34a and U6 miRNA 
TaqMan expression assays (Applied Biosystems). 
Relative miR-34a expression was determined using 
the gene comparative CT method. For gene expression 
analysis, 200 ng of total RNA was reverse transcribed 
using ThermoScriptTM RT-PCR system for first strand 
cDNA synthesis (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s instructions. Gene expression was 
then determined by qPCR using the KiCq Start SYBR 
Green kit (Sigma, St. Louis, MO). The primers sequences 
used for gene expression SYBR Green qPCR are listed in 
Supplemental Table 1.
Immunoblotting
Protein lysates were prepared using RIPA B lysis 
buffer (150 mM NaCl, 20 mM sodium phosphate buffer, 
5 mM ethylenediaminetetraacetic acid, and 1% Triton 
X-100, pH 7.4) along with 1 tablet of protease and 
phosphatase inhibitor cocktail (Roche, Indianapolis, 
IN). For in vivo samples, tumor sections were cut and 
homogenized by magnetic beads in RIPA A lysis buffer 
(1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 
150mM NaCl, 5mM EDTA, 5mM sodium pyrophosphate, 
20mM sodium phosphate buffer, pH 7.4) along with 1 
tablet of protease and phosphatase inhibitor cocktail). Total 
protein lysates (15 or 30 µg) were loaded onto an 8% or 
12% polyacrylamide gel, which were then transferred to a 
polyvinylidene difluoride (PVDF) membrane and blocked 
with 5% milk in tris-buffered saline with Tween-20. 
Membranes were probed with specific primary antibodies: 
c-Met (C12), c-Myc (Santa Cruz Biotechnology, Santa 
Cruz, CA), Axl, cleaved caspase 3, LC3B, p62/SQSTM1, 
Beclin-1, ATG5 and ATG7 (Cell Signaling, Danvers, MA), 
GAPDH (Millipore, Temacula, CA), and horseradish 
peroxidase-conjugated secondary goat anti-mouse or goat 
ant-rabbit antibody (Bio-Rad, Hercules, CA).
Transmission electron microscopy (TEM)
Samples fixed with a solution containing 3% 
glutaraldehyde plus 2% paraformaldehyde in 0.1 M 
cacodylate buffer, pH 7.3 were washed in 0.1 M cacodylate 
buffer and treated with 0.1% Millipore-filtered buffered 
tannic acid, post-fixed with 1% buffered osmium tetroxide 
for 30 min, and stained en bloc with 1% Millipore-filtered 
uranyl acetate. The samples were washed several times 
in water, then dehydrated in increasing concentrations of 
ethanol, infiltrated, and embedded in LX-112 medium. 
The samples were polymerized in a 60°C oven for 2 days. 
Ultrathin sections were cut in a Leica Ultracut microtome 
(Leica, Deerfield, IL), stained with uranyl acetate and 
lead citrate in a Leica EM Stainer, and examined in a JEM 
1010 transmission electron microscope (JEOL, USA, 
Inc., Peabody, MA) at an accelerating voltage of 80 kV. 
Digital images were obtained using AMT Imaging System 
(Advanced Microscopy Techniques Corp, Danvers, MA).
siRNA and shRNA transfection
The sequences of ATG5 and ATG7 chemical siRNAs 
were purchased from Life Technologies. Validated siRNAs 
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for four isoforms of ATG4 (ATG4A, 4B, 4C and 4D) 
were purchased from Sigma. PC3 cells were transfected 
with 100 nM of siATG5 or siATG7 or 30 nM each of 
siATG4 sequences using DharmaFECT1 (GE Healthcare, 
Lafayette, CO) transfection reagent and 24 hours later, 
siATG5, siATG7 or siATG4 cells were transfected with 
N.C. or miR-34a using Lipofectamine 2000. Lentiviral 
shRNA constructs for Beclin-1 were provided by The 
University of Texas MD Anderson Cancer Center 
(UTMDACC) shRNA and ORFeome core facility. GIPZ 
lentiviral shBeclin-1 (GE Healthcare) constructs were 
packaged in lentivirus and PC3 cells were transduced with 
the concentrated viral titer in growth media containing 8 
μg/ml polybrene and GFP+ cells were sorted by BD FACS 
Aria II following which they were transfected with either 
N.C. or miR-34a mimics for 72 hours.
Animal studies
One million PC3MM2 cells were injected sub-
cutaneously into nude mice. One week after cell injection, 
mice were randomized and divided into control group or 
miR-34a treatment group. The control group received 
negative control (N.C.) miRNA (scrambled sequence of 
negative control miRNA tested and validated to confirm 
that it does not interfere with known miRNA functions) 
encapsulated in chitosan nanoparticles (N.C.-CH) while 
the miR-34a group received miR-34a mimic encapsulated 
in chitosan nanoparticles (miR-34a-CH). Chitosan 
(CH) nanoparticles complexed with N.C. or miR-34a 
were prepared as described previously [57]. Briefly, CH 
solution was obtained by dissolving CH in 0.25% acetic 
acid and nanoparticles were spontaneously generated 
by the addition of TPP (0.25% w/v) and either N.C. or 
miR-34a at concentration of 1μg/μL under constant 
stirring at room temperature. After incubating at 4˚C for 
40 min, N.C.-CH or miR-34a-CH nanoparticles were 
collected by centrifugation at 14,000 rpm for 40 minutes 
at 4˚C. The pellet was washed 3 times to remove unbound 
chemicals or N.C./miR-34a and N.C.-CH and miR-34a-
CH nanoparticles were dissolved in water. 5μg/100μL of 
nanoparticles were delivered through tail vein injection 
per mouse, every three days for two weeks. Tumor volume 
as measured by caliper instrument was recorded. After 
two weeks of treatment, the animals were sacrificed and 
tumors harvested for protein, in situ hybridization (ISH) 
and immunofluorescence (IF). For intra-femur experiment, 
1x106 PC3MM2-LG cells labeled with luciferase and GFP 
were injected in the femur of the mice. Ten days after cell 
injection, mice were randomized into two groups- control 
and miR-34a and N.C.-CH or miR-34a-CH nanoparticles 
were delivered (5μg/100μL of nanoparticles) respectively 
via tail-vein injection every three days for three weeks. 
Tumor growth was monitored through bioluminescence 
imaging (IVIS 200) and tumor volume was measured 
before the start of treatment and at the end of treatment by 
magnetic resonance imaging (MRI) (Bruker 4.7T). Micro 
CT imaging was performed to visualize bone integrity at 
the end of the experiment on the Explore Locus RS pre-
clinical in vivo scanner (GE Medical Systems, London 
Ontario).
Statistics
Student’s t tests were used for all statistical 
comparisons and a p value of <0.05 was considered 
statistically significant. Statistical analyses were 
performed using the GraphPad Prism software.
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